AGP Executive Report
Last update: 8 minutes agoOptogenetics Breakthrough: The 2026 Nobel Prize in Physiology or Medicine went to Karl Deisseroth and colleagues for optogenetics, a tool that lets scientists control specific cells with light—opening new paths for treating disorders like Parkinson’s and epilepsy. Biotech Dealmaking: Novartis signed a licensing deal worth up to $7.8B with China’s Abogen Biosciences for an mRNA autoimmune therapy (ABO2203), signaling continued global demand for Chinese immunology pipelines. Clinical Trial Acceleration: The U.S. FDA launched an expedited IND pilot (“Operation TrialBlazer”) to speed early clinical trial entry—an effort to keep pace with countries including China. Diabetes Drug Results: Orforglipron showed stronger A1C and weight reductions than oral semaglutide in a phase 3 trial, with data spanning multiple countries including China. Public Health Watch: U.S. officials are monitoring a reported pneumonic plague death in Russia tied to an anti-plague lab, while information-sharing remains limited. Food & Health: A study links higher cat density with greater happiness in wealthier countries, but notes sadness rises where exposure to the cat parasite Toxoplasma gondii is higher.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/24990778-912932933-69ad66ff9a88b963b53a43ee2436f89da07d52ad-1280x720-100x56.jpeg)
